3M Pharmaceuticals and Takeda to Collaborate on Potential Treatment for Cervical High-Risk HPV Infection and Cervical Dysplasia
3M and Takeda Pharmaceutical Company Limited announced that the two companies entered into an exclusive co-development and joint marketing agreement to collaborate on a potential topical treatment for cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia.
The compound is currently in early stage (Phase I) clinical testing. Under the terms of this agreement, 3M and Takeda will share further costs of development. Upon successful clinical development and regulatory approvals, the companies will jointly commercialize in the United States and European Union. Takeda will retain exclusive rights in Japan and certain Asian countries, and 3M will have exclusive commercialization rights in all other areas of the world.
The compound is part of the family of immune response modifier (IRM) molecules developed by 3M Pharmaceuticals. IRMs act in a novel way to stimulate the human body's immune system to fight virus-infected cells and tumor cells.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
QIAGEN names Thierry Bernard as Chief Executive Officer
Horizon Discovery Appoints Richard Vellacott as Chief Financial Officer

European Innovation Council funds Dermagnostix with 2.5 million euros - Start-up has made it its mission to push back the diagnostic boundaries
